

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/539,220	First Named Inventor: Heron et al.
Filing Date: June 17, 2005	Attorney Docket No.: 100938-1P US
Examiner: Tamthom Ngo Truong	Group Art Unit: 1624
Customer No.: 44992	Confirmation No.: 4585
Title: Phosphonooxy Quinazoline Deri	vatives and their Pharmaceutical Use

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## CORRECTION OF INVENTORSHIP UNDER CFR § 1.48

Dear Sir:


Under the provisions of CFR § 1.48 Applicants hereby request correction of the inventorship for the above-referenced application in that the prosecution of the nonprovisional application has resulted in the amendment or cancellation of claims so that fewer than all of the currently named inventors are the actual inventors of the invention being claimed in the nonprovisional application.

Applicants assert that the correct inventors were originally named in a nonprovisional application, but through amendment or cancellation of claims during prosecution, Applicants now request the deletion of the following person(s) who are no longer inventors of the claimed subject matter:

Frederic Henri Jung and Georges, Rene Pasquet

Accordingly, the correct inventors are:

Nicola, Murdoch Heron and Andrew Austen Mortlock







**Application No.: 10/539,220** 

Docket No.: 100938-1P US

The Commissioner is hereby authorized to charge the fee under § 1.17(i) in the amount of \$130 to deposit account No. 50-3231, referencing Attorney Docket No. 100938-1P US.

Respectfully submitted, /Jacob G. Weintraub/

Name: Jacob G. Weintraub, Esq. Dated: February 12, 2009

Reg. No.: 56,469

Phone No.: 781 839 4182

Global Intellectual Property, Patents,

AstraZeneca R&D Boston, 35, Gatehouse Drive, Waltham, MA 02451